<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511988</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A02251-38</org_study_id>
    <nct_id>NCT04511988</nct_id>
  </id_info>
  <brief_title>Using Liquid Biopsy in Newly Diagnosed Patients With High Grade Adenocarcinoma of Ovarian Origin, Fallopian Tubes or Primary Peritoneal</brief_title>
  <acronym>BOVARY CE</acronym>
  <official_title>Evaluation of Clonal Heterogeneity and Tumor Evolution Using Liquid Biopsy in Newly Diagnosed Patients With High Grade Adenocarcinoma of Ovarian Origin, Fallopian Tubes or Primary Peritoneal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BOVARY-CE is a monocentric, pilot, longitudinal, real-life study with a total duration of 36&#xD;
      months. The purpose of this study is to assess the feasibility of using liquid biopsy as a&#xD;
      substitute for tissue multisampling, in order to describe clonal heterogeneity and tumor&#xD;
      evolution in patients with ovarian cancer. The method involves the inclusion of 20 patients&#xD;
      with high-grade ovarian adenocarcinoma, fallopian tubes or primary peritoneal origin, not&#xD;
      pretreated, newly diagnosed, and eligible for treatment who will participate in the research.&#xD;
      These patients will have several samples throughout their treatment for a period of 2 years:&#xD;
      blood samples which will be taken at each therapeutic moment of interest.&#xD;
&#xD;
      Tissue samples which will be taken at the time of the diagnostic laparoscopy and at the time&#xD;
      of surgery.&#xD;
&#xD;
      The concentration of cfDNA and tumor heterogeneity will be used to predict disease-related&#xD;
      events defined as relapse, progression or death.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Using the concentration of cfDNA to predict disease events</measure>
    <time_frame>12 months</time_frame>
    <description>cfDNA concentration (ng / µl)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>blood sample (20 ml) and biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diagnostic Test</intervention_name>
    <description>blood sample (20 ml) and biopsy</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Patient with non-treated high grade serous and endometrioid carcinoma of ovarian,&#xD;
             fallopian tube, or primary peritoneal origin proven cytologically or histologically at&#xD;
             inclusion and eligible for treatment&#xD;
&#xD;
          -  Patient eligible for an upfront surgery or pretherapeutic coelioscopy&#xD;
&#xD;
          -  Adequate haemoglobin rate ≥ 9 g/dL&#xD;
&#xD;
          -  Patient affiliated to a social security scheme&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Any concurrent severe and/or uncontrolled medical conditions which could compromise&#xD;
             participation in the study&#xD;
&#xD;
          -  Contraindication to blood samples of 20 mL&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Ongoing treatment for the newly diagnosed cancer or the recurrence&#xD;
&#xD;
          -  Other cancers treated within the last 5 years&#xD;
&#xD;
          -  Patient under guardianship or curatorship or deprived of liberty&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LEUFFLEN Léa, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MERLIN Jean Louis, PU PH</last_name>
    <phone>+33 (0)3 83 65 60 62</phone>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HERMAN Marie Aude</last_name>
    <phone>+33 (0)3 83 59 86 68</phone>
    <email>m.herman@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54506</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LEUFFLEN Léa, MD PhD</last_name>
      <phone>+33 (0)3 83 59 84 51</phone>
      <email>l.leufflen@nancy.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>GAVOILLE Céline, MD PhD</last_name>
      <phone>+33 (0)3 83 59 83 31</phone>
      <email>c.gavoille@nancy.unicancer.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

